Mitchell Mcleod Pugh & Williams Inc. Has $547,000 Stake in McKesson Co. (NYSE:MCK)

Mitchell Mcleod Pugh & Williams Inc. lessened its position in shares of McKesson Co. (NYSE:MCK) by 11.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 959 shares of the company’s stock after selling 121 shares during the period. Mitchell Mcleod Pugh & Williams Inc.’s holdings in McKesson were worth $547,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in the company. Thrivent Financial for Lutherans lifted its holdings in shares of McKesson by 5.5% in the second quarter. Thrivent Financial for Lutherans now owns 19,036 shares of the company’s stock worth $11,117,000 after acquiring an additional 998 shares during the last quarter. Westwood Holdings Group Inc. bought a new position in McKesson in the 2nd quarter valued at approximately $2,596,000. Kayne Anderson Rudnick Investment Management LLC boosted its position in McKesson by 21.1% in the second quarter. Kayne Anderson Rudnick Investment Management LLC now owns 13,545 shares of the company’s stock valued at $7,911,000 after buying an additional 2,363 shares in the last quarter. Kowal Investment Group LLC increased its holdings in shares of McKesson by 6.5% during the second quarter. Kowal Investment Group LLC now owns 474 shares of the company’s stock worth $277,000 after buying an additional 29 shares in the last quarter. Finally, Frank Rimerman Advisors LLC lifted its stake in shares of McKesson by 14,900.0% in the 2nd quarter. Frank Rimerman Advisors LLC now owns 900 shares of the company’s stock valued at $526,000 after acquiring an additional 894 shares during the last quarter. 85.07% of the stock is owned by institutional investors.

Insider Activity at McKesson

In other McKesson news, EVP Leann B. Smith sold 579 shares of the firm’s stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $572.79, for a total value of $331,645.41. Following the completion of the transaction, the executive vice president now owns 864 shares in the company, valued at $494,890.56. This trade represents a 40.12 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.11% of the stock is owned by company insiders.

McKesson Price Performance

Shares of NYSE MCK opened at $592.69 on Tuesday. The company has a 50-day moving average price of $595.11 and a 200-day moving average price of $561.01. The stock has a market capitalization of $75.24 billion, a P/E ratio of 30.69, a P/E/G ratio of 1.26 and a beta of 0.52. McKesson Co. has a 1 year low of $464.42 and a 1 year high of $637.51.

McKesson (NYSE:MCK) last announced its quarterly earnings results on Wednesday, November 6th. The company reported $7.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.88 by $0.19. The business had revenue of $93.65 billion during the quarter, compared to the consensus estimate of $89.33 billion. McKesson had a negative return on equity of 207.50% and a net margin of 0.77%. McKesson’s revenue was up 21.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $6.23 earnings per share. As a group, equities research analysts anticipate that McKesson Co. will post 32.73 earnings per share for the current fiscal year.

McKesson Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, January 2nd. Investors of record on Monday, December 2nd were paid a dividend of $0.71 per share. This represents a $2.84 dividend on an annualized basis and a dividend yield of 0.48%. The ex-dividend date of this dividend was Monday, December 2nd. McKesson’s payout ratio is currently 14.71%.

Wall Street Analyst Weigh In

MCK has been the subject of a number of recent research reports. Mizuho started coverage on McKesson in a report on Wednesday, December 4th. They issued a “neutral” rating and a $630.00 target price for the company. Wells Fargo & Company raised their price objective on shares of McKesson from $535.00 to $641.00 and gave the company an “equal weight” rating in a report on Friday, December 13th. Morgan Stanley upped their price target on shares of McKesson from $612.00 to $642.00 and gave the company an “overweight” rating in a research report on Tuesday, December 17th. Bank of America cut their price target on shares of McKesson from $680.00 to $650.00 and set a “buy” rating on the stock in a report on Monday, January 6th. Finally, Baird R W upgraded McKesson from a “hold” rating to a “strong-buy” rating in a report on Thursday, November 7th. Two analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $646.14.

About McKesson

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.